Skip to content
2000
Volume 20, Issue 2
  • ISSN: 1574-3624
  • E-ISSN: 2212-389X

Abstract

Novo Nordisk has innovated a subcutaneous formulation of semaglutide, branded as Ozempic, which functions as a modified human glucagon-like peptide-1 (GLP-1) analogue. This formulation is tailored to address the treatment needs of individuals diagnosed with type 2 diabetes mellitus (T2DM). By providing a modified version of the naturally occurring hormone GLP-1, Ozempic offers a therapeutic approach that targets glucose metabolism and helps regulate blood sugar levels in patients with this condition. It has been endorsed as a secondary treatment for improving glycemic control in T2DM, and it is currently being investigated for its potential in combating obesity. Studies have demonstrated that semaglutide is safe for use in both adult and elderly patients with renal or hepatic conditions, requiring no adjustment in dosage. Semaglutide is a GLP-1RA drug that is used to reduce chronic obesity and the dosage used is 2.4 mg for the patients. The study highlighted the effects of the semaglutide drug on patients with obesity and T2DM. The drug exerts several adverse side effects on co-morbid patients with T2DM and obesity. Semaglutide targets the specific area of the brain (GLP-1 receptors), which is beneficial for the regulation of the appetite and helps to manage weight. Semaglutide imitates the function of incretin. The fluctuation of the blood sugar level can be controlled with semaglutide. The long-term health complications related to diabetes can be decreased with semaglutide. This study highlights the safety concerns and risk factors associated with semaglutide.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cst/10.2174/0115743624346660250317013032
2025-03-26
2025-09-26

  • From This Site

    /content/journals/cst/10.2174/0115743624346660250317013032
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. DaviesM. FærchL. JeppesenO.K. PaksereshtA. PedersenS.D. PerreaultL. RosenstockJ. ShimomuraI. ViljoenA. WaddenT.A. LingvayI. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): A randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.Lancet20213971027897198410.1016/S0140‑6736(21)00213‑033667417
     [Google Scholar]
  2. WaddenT.A. BaileyT.S. BillingsL.K. DaviesM. FriasJ.P. KorolevaA. LingvayI. O’NeilP.M. RubinoD.M. SkovgaardD. WallensteinS.O.R. GarveyW.T. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: The STEP 3 randomized clinical trial.JAMA2021325141403141310.1001/jama.2021.183133625476
     [Google Scholar]
  3. RubinoD.M. GreenwayF.L. KhalidU. O’NeilP.M. RosenstockJ. SørrigR. WaddenT.A. WizertA. GarveyW.T. Arauz-PachecoC. CannonK. DowneyH.J. Fitz-PatrickD. GeohasJ. GeretyG. GilbertJ. HollanderP. KleinE. LauferK. O’DonnellP. RosenblitP. TothP. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: The STEP 8 randomized clinical trial.JAMA2022327213815010.1001/jama.2021.2361935015037
     [Google Scholar]
  4. NauckM.A. QuastD.R. Cardiovascular safety and benefits of semaglutide in patients with type 2 diabetes: Findings from SUSTAIN 6 and PIONEER 6.Front. Endocrinol. (Lausanne)20211264556610.3389/fendo.2021.64556633854484
     [Google Scholar]
  5. UzoigweC. LiangY. WhitmireS. PaprockiY. Semaglutide once-weekly persistence and adherence versus other GLP-1 RAs in patients with type 2 diabetes in a US real-world setting.Diab. Ther.20211251475148910.1007/s13300‑021‑01053‑733837922
     [Google Scholar]
  6. KnudsenL.B. LauJ. The discovery and development of liraglutide and semaglutide.Front. Endocrinol. (Lausanne)20191015510.3389/fendo.2019.0015531031702
     [Google Scholar]
  7. DaviesM. PieberT.R. Hartoft-NielsenM.L. HansenO.K.H. JabbourS. RosenstockJ. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: A randomized clinical trial.JAMA2017318151460147010.1001/jama.2017.1475229049653
     [Google Scholar]
  8. DhillonS. Semaglutide: First global approval.Drugs201878227528410.1007/s40265‑018‑0871‑029363040
     [Google Scholar]
  9. ZhangL. ZhangL. LiL. HölscherC. Semaglutide is neuroprotective and reduces α-synuclein levels in the chronic MPTP mouse model of Parkinson’s disease.J. Parkinsons Dis.20199115717110.3233/JPD‑18150330741689
     [Google Scholar]
  10. SuzukiR. BrownG.A. ChristopherJ.A. ScullyC.C.G. CongreveM. Recent developments in therapeutic peptides for the glucagon-like peptide 1 and 2 receptors.J. Med. Chem.202063390592710.1021/acs.jmedchem.9b0083531577440
     [Google Scholar]
  11. PeterR. BainS.C. Safety of injectable semaglutide for type 2 diabetes.Expert Opin. Drug Saf.202019778579810.1080/14740338.2020.177223032428416
     [Google Scholar]
  12. GuglielmiV. BettiniS. SbracciaP. BusettoL. PellegriniM. YumukV. ColaoA.M. El GhochM. MuscogiuriG. Beyond weight loss: Added benefits could guide the choice of anti-obesity medications.Curr. Obes. Rep.202312212714610.1007/s13679‑023‑00502‑737209215
     [Google Scholar]
  13. ChristouG.A. KatsikiN. BlundellJ. FruhbeckG. KiortsisD.N. Semaglutide as a promising antiobesity drug.Obes. Rev.201920680581510.1111/obr.1283930768766
     [Google Scholar]
  14. BergmannN.C. DaviesM.J. LingvayI. KnopF.K. Semaglutide for the treatment of overweight and obesity: A review.Diab. Obes. Metab.2023251183510.1111/dom.1486336254579
     [Google Scholar]
  15. RyanD.H. Next generation antiobesity medications: Setmelanotide, semaglutide, tirzepatide and bimagrumab: What do they mean for clinical practice?J. Obes. Metab. Syndr.202130319620810.7570/jomes2103334518444
     [Google Scholar]
  16. Di FolcoU. VallecorsaN. NardoneM.R. PantanoA.L. TubiliC. Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes.Acta Diabetol.202259101287129410.1007/s00592‑022‑01936‑635842847
     [Google Scholar]
  17. Aviles BuenoB. SolerM.J. Perez-BelmonteL. Jimenez MillanA. Rivas RuizF. Garcia de LucasM.D. Semaglutide in type 2 diabetes with chronic kidney disease at high risk progression—real-world clinical practice.Clin. Kidney J.20221581593160010.1093/ckj/sfac09635892023
     [Google Scholar]
  18. MasakiT. OzekiY. YoshidaY. OkamotoM. MiyamotoS. GotohK. ShibataH. Glucagon-like peptide-1 receptor agonist semaglutide improves eating behavior and glycemic control in japanese obese type 2 diabetic patients.Metabolites202212214710.3390/metabo1202014735208221
     [Google Scholar]
  19. HeerspinkH.J.L. ApperlooE. DaviesM. DickerD. KandlerK. RosenstockJ. SørrigR. LawsonJ. ZeuthenN. CherneyD. Effects of semaglutide on albuminuria and kidney function in people with overweight or obesity with or without type 2 diabetes: Exploratory analysis from the STEP 1, 2, and 3 trials.Diab. Care202346480181010.2337/dc22‑188936801984
     [Google Scholar]
  20. UchiyamaS. SadaY. MiharaS. SasakiY. SoneM. TanakaY. Oral semaglutide induces loss of body fat mass without affecting muscle mass in patients with type 2 diabetes.J. Clin. Med. Res.202315737738310.14740/jocmr498737575352
     [Google Scholar]
  21. de la FlorJ.C. DeiraJ. MonzónT. ValgaF. AlbarracínC. RuizE. RodelesM. Efficacy and safety of semaglutide in a diabetic and obese patient on incremental hemodialysis. Does it also contribute to preserving residual renal function?Nefrología (Engl. Ed.)202343450150310.1016/j.nefroe.2023.08.00537658008
     [Google Scholar]
  22. BerraC.C. RossiM.C. MiraniM. Ceccarelli CeccarelliD. RomanoC. SassiL. PerettiE. FavacchioG. PastoreI. FoliniL. GrazianoG. LunatiM.E. SolerteS.B. FiorinaP. Real world effectiveness of subcutaneous semaglutide in type 2 diabetes: A retrospective, cohort study (Sema-MiDiab01).Front. Endocrinol. (Lausanne)202313109945110.3389/fendo.2022.109945136743930
     [Google Scholar]
  23. ThethiT.K. PratleyR. MeierJ.J. Efficacy, safety and cardiovascular outcomes of once‐daily oral semaglutide in patients with type 2 diabetes: The pioneer programme.Diab. Obes. Metab.20202281263127710.1111/dom.1405432267058
     [Google Scholar]
  24. BuseJ.B. BodeB.W. MertensA. ChoY.M. ChristiansenE. HertzC.L. NielsenM.A. PieberT.R. Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: A 52-week, randomized, open-label extension of the PIONEER 7 trial.BMJ Open Diabetes Res. Care202082e00164910.1136/bmjdrc‑2020‑00164933318068
     [Google Scholar]
  25. SmitsM.M. Van RaalteD.H. Safety of semaglutide.Front. Endocrinol. (Lausanne)20211264556310.3389/fendo.2021.64556334305810
     [Google Scholar]
  26. ChaoA.M. TronieriJ.S. AmaroA. WaddenT.A. Clinical insight on semaglutide for chronic weight management in adults: Patient selection and special considerations.Drug Des. Devel. Ther.2022164449446110.2147/DDDT.S36541636601368
     [Google Scholar]
  27. WitM. Trujillo-VieraJ. StrohmeyerA. KlingensporM. HankirM. SumaraG. When fat meets the gut—focus on intestinal lipid handling in metabolic health and disease.EMBO Mol. Med.2022145e1474210.15252/emmm.20211474235437952
     [Google Scholar]
  28. RubinoD. AbrahamssonN. DaviesM. HesseD. GreenwayF.L. JensenC. LingvayI. MosenzonO. RosenstockJ. RubioM.A. RudofskyG. TadayonS. WaddenT.A. DickerD. FribergM. SjödinA. DickerD. SegalG. MosenzonO. SabbahM. SoferY. VishlitzkyV. MeestersE.W. SerlieM. van BonA. CardosoH. FreitasP. Carneiro de MeloP. MonteiroM. MonteiroM. RodriguesD. BadatA. JoshiP. LatiffG. MithaE.A. SnymanH.H. van NieuwenhuizenE. González AlbarránO. CaixasA. de al CuestaC. Garcia LunaP.P. Morales PortilloC. Mezquita RayaP. RubioM.A. AbrahamssonN. HoffstedtJ. von WowernF. UddmanE. Bach-KliegelB. BeuschleinF. BilzS. GolayA. RudofskyG. StreyC. FadieienkoG. KoseiN. TatarchukT. VelychkoV. ZinychO. AronoffS.L. BaysH.E. BrockmyreA.P. CallR.S. CrumpC. DesouzaC.V. EspinosaV. FreeA.L. GandyW.H. GellerS.A. GottschlichG.M. GreenwayF.L. Han-ConradL. HarperW. HermanL. HewittM. HollanderP. KasterS.R. ManessisA. MartinF.A. McNeillR.E. MurrayA.V. NorwoodP.C. ReedJ.C.H. RosenstockJ. RubinoD.M. SchearM.J. WarrenM.L. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial.JAMA2021325141414142510.1001/jama.2021.322433755728
     [Google Scholar]
  29. OkamotoA. YokokawaH. NagamineT. FukudaH. HisaokaT. NaitoT. Efficacy and safety of semaglutide in glycemic control, body weight management, lipid profiles and other biomarkers among obese type 2 diabetes patients initiated or switched to semaglutide from other GLP-1 receptor agonists.J. Diabetes Metab. Disord.20212022121212810.1007/s40200‑021‑00899‑934900848
     [Google Scholar]
  30. AlorfiN.M. AlgarniA.S. Clinical impact of semaglutide, a glucagon-like peptide-1 receptor agonist, on obesity management: A review.Clin. Pharmacol.202214616710.2147/CPAA.S37474135958046
     [Google Scholar]
  31. KreinerF.F. SchytzP.A. HeerspinkH.J.L. von ScholtenB.J. IdornT. Obesity-related Kidney Disease: Current understanding and future perspectives.Biomedicines2023119249810.3390/biomedicines1109249837760939
     [Google Scholar]
  32. AndreasenC.R. AndersenA. KnopF.K. VilsbøllT. How glucagon-like peptide 1 receptor agonists work.Endocr. Connect.2021107R200R21210.1530/EC‑21‑013034137731
     [Google Scholar]
  33. ElsanhouryA. NelkiV. KelleS. Van LinthoutS. TschöpeC. Epicardial fat expansion in diabetic and obese patients with heart failure and preserved ejection fraction—a specific HFpEF phenotype.Front. Cardiovasc. Med.2021872069010.3389/fcvm.2021.72069034604353
     [Google Scholar]
  34. BruciA. TuccinardiD. TozziR. BalenaA. SantucciS. FrontaniR. MarianiS. BascianiS. SperaG. GnessiL. LubranoC. WatanabeM. Very low-calorie ketogenic diet: A safe and effective tool for weight loss in patients with obesity and mild kidney failure.Nutrients202012233310.3390/nu1202033332012661
     [Google Scholar]
  35. DavenportA.P. ScullyC.C.G. de GraafC. BrownA.J.H. MaguireJ.J. Advances in therapeutic peptides targeting G protein-coupled receptors.Nat. Rev. Drug Discov.202019638941310.1038/s41573‑020‑0062‑z32494050
     [Google Scholar]
  36. GranhallC. DonsmarkM. BlicherT.M. GolorG. SøndergaardF.L. ThomsenM. BækdalT.A. Safety and pharmacokinetics of single and multiple ascending doses of the novel oral human GLP-1 analogue, oral semaglutide, in healthy subjects and subjects with type 2 diabetes.Clin. Pharmacokinet.201958678179110.1007/s40262‑018‑0728‑430565096
     [Google Scholar]
  37. NauckM.A. QuastD.R. WefersJ. MeierJ.J. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art.Mol. Metab.20214610110210.1016/j.molmet.2020.10110233068776
     [Google Scholar]
  38. MarxN. HusainM. LehrkeM. VermaS. SattarN. GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes.Circulation2022146241882189410.1161/CIRCULATIONAHA.122.05959536508493
     [Google Scholar]
  39. HusainM. BirkenfeldA.L. DonsmarkM. DunganK. EliaschewitzF.G. FrancoD.R. JeppesenO.K. LingvayI. MosenzonO. PedersenS.D. TackC.J. ThomsenM. VilsbøllT. WarrenM.L. BainS.C. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes.N. Engl. J. Med.2019381984185110.1056/NEJMoa190111831185157
     [Google Scholar]
  40. MeierJ.J. Efficacy of semaglutide in a subcutaneous and an oral formulation.Front. Endocrinol. (Lausanne)20211264561710.3389/fendo.2021.64561734248838
     [Google Scholar]
  41. GhusnW. De la RosaA. SacotoD. Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity.JAMA. Netw. Open.202259e223198210.1001/jamanetworkopen.2022.3198236121652
     [Google Scholar]
  42. MurvelashviliN. XieL. SchellingerJ.N. MathewM.S. MarroquinE.M. LingvayI. MessiahS.E. AlmandozJ.P. Effectiveness of semaglutide versus liraglutide for treating post‐metabolic and bariatric surgery weight recurrence.Obesity (Silver Spring)20233151280128910.1002/oby.2373636998152
     [Google Scholar]
  43. Solis-HerreraC. KaneM.P. TriplittC. Current understanding of sodium n-(8-[2-hydroxylbenzoyl] amino) caprylate (SNAC) as an absorption enhancer: The oral semaglutide experience.Clin. Diab.2024421748610.2337/cd22‑011838230324
     [Google Scholar]
  44. ArodaV.R. BlondeL. PratleyR.E. A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes.Rev. Endocr. Metab. Disord.202223597999410.1007/s11154‑022‑09735‑835838946
     [Google Scholar]
  45. KalraS. DasS. ZargarA.H. A review of oral semaglutide available evidence: A new era of management of diabetes with peptide in a pill form.Ind. J. Endocrinol. Metab.20222629810510.4103/ijem.ijem_522_2135873937
     [Google Scholar]
  46. AndersenA. KnopF.K. VilsbøllT. A pharmacological and clinical overview of oral semaglutide for the treatment of type 2 diabetes.Drugs20218191003103010.1007/s40265‑021‑01499‑w33964002
     [Google Scholar]
  47. HjerpstedJ.B. FlintA. BrooksA. AxelsenM.B. KvistT. BlundellJ. Semaglutide improves postprandial glucose and lipid metabolism, and delays first‐hour gastric emptying in subjects with obesity.Diab. Obes. Metab.201820361061910.1111/dom.1312028941314
     [Google Scholar]
  48. BlundellJ. GibbonsC. HoffS. DahlK. SøndergaardF. BækdalT. Oral semaglutide reduces appetite and energy intake and improves control of eating in subjects with type 2 diabetes.Diabetologia201962Suppl. 1S363
     [Google Scholar]
  49. KiefferT.J. Francis HabenerJ. The glucagon-like peptides.Endocr. Rev.199920687691310.1210/edrv.20.6.038510605628
     [Google Scholar]
  50. HolstJ.J. The physiology of glucagon-like peptide 1.Physiol. Rev.20078741409143910.1152/physrev.00034.200617928588
     [Google Scholar]
  51. MüllerT.D. BlüherM. TschöpM.H. DiMarchiR.D. Anti-obesity drug discovery: Advances and challenges.Nat. Rev. Drug Discov.202221320122310.1038/s41573‑021‑00337‑834815532
     [Google Scholar]
  52. LézardL. Semaglutide 2.4 mg injection demonstrated significant weight loss versus placebo when added to intensive behavioral therapy.2020Available from: www.prnewswire.com/news-releases/semaglutide-2-4-mg-injection-demonstrated-significant-weight-loss-versus-placebo-when-added-to-intensive-behavioral-therapy-301167230.html (Accessed on: Nov 05, 2020).
  53. MartinezT.F. VaughanJ. SaghatelianA. Insights into GLP-1 receptor activation with a nonpeptide agonist.Biochemistry202059161549155010.1021/acs.biochem.0c0018032297516
     [Google Scholar]
  54. BandoH. IwatsukiN. OkadaM. OgawaT. SakamotoK. Improvement of obesity and type 2 diabetes (T2D) by oral semaglutide (Rybelsus) and super-low carbohydrate diet (LCD).SunText. Rev. Endocr. Care.202321110
     [Google Scholar]
  55. OgawaH. BandoH. AbeT. NagahiroS. NakanishiM. WatanabeO. Efficacy for reduction of HbA1c and body weight by oral semaglutide (Rybelsus).SunTe. Rev. Med. Clini. Res.202233162
     [Google Scholar]
  56. NewsomeP.N. BuchholtzK. CusiK. LinderM. OkanoueT. RatziuV. SanyalA.J. SejlingA.S. HarrisonS.A. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis.N. Engl. J. Med.2021384121113112410.1056/NEJMoa202839533185364
     [Google Scholar]
  57. TargherG. CoreyK.E. ByrneC.D. RodenM. The complex link between NAFLD and type 2 diabetes mellitus — mechanisms and treatments.Nat. Rev. Gastroenterol. Hepatol.202118959961210.1038/s41575‑021‑00448‑y33972770
     [Google Scholar]
  58. FergusonD. FinckB.N. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus.Nat. Rev. Endocrinol.202117848449510.1038/s41574‑021‑00507‑z34131333
     [Google Scholar]
  59. WildingJ.P.H. BatterhamR.L. CalannaS. DaviesM. Van GaalL.F. LingvayI. McGowanB.M. RosenstockJ. TranM.T.D. WaddenT.A. WhartonS. YokoteK. ZeuthenN. KushnerR.F. Once-weekly semaglutide in adults with overweight or obesity.N. Engl. J. Med.202138411989100210.1056/NEJMoa203218333567185
     [Google Scholar]
  60. HoltR.I.G. DeVriesJ.H. Hess-FischlA. HirschI.B. KirkmanM.S. KlupaT. LudwigB. NørgaardK. PettusJ. RenardE. SkylerJ.S. SnoekF.J. WeinstockR.S. PetersA.L. The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).Diab. Care202144112589262510.2337/dci21‑004334593612
     [Google Scholar]
  61. WhartonS. BatterhamR.L. BhattaM. BuscemiS. ChristensenL.N. FriasJ.P. JódarE. KandlerK. RigasG. WaddenT.A. GarveyW.T. Two‐year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5.Obesity (Silver Spring)202331370371510.1002/oby.2367336655300
     [Google Scholar]
  62. GarveyW.T. BatterhamR.L. BhattaM. BuscemiS. ChristensenL.N. FriasJ.P. JódarE. KandlerK. RigasG. WaddenT.A. WhartonS. Two-year effects of semaglutide in adults with overweight or obesity: The STEP 5 trial.Nat. Med.202228102083209110.1038/s41591‑022‑02026‑436216945
     [Google Scholar]
  63. WeghuberD. BarrettT. Barrientos-PérezM. GiesI. HesseD. JeppesenO.K. KellyA.S. MastrandreaL.D. SørrigR. ArslanianS. Once-weekly semaglutide in adolescents with obesity.N. Engl. J. Med.2022387242245225710.1056/NEJMoa220860136322838
     [Google Scholar]
  64. LincoffA.M. Brown-FrandsenK. ColhounH.M. DeanfieldJ. EmersonS.S. EsbjergS. Hardt-LindbergS. HovinghG.K. KahnS.E. KushnerR.F. LingvayI. OralT.K. MichelsenM.M. PlutzkyJ. TornøeC.W. RyanD.H. Semaglutide and cardiovascular outcomes in obesity without diabetes.N. Engl. J. Med.2023389242221223210.1056/NEJMoa230756337952131
     [Google Scholar]
  65. KosiborodM.N. AbildstrømS.Z. BorlaugB.A. ButlerJ. RasmussenS. DaviesM. HovinghG.K. KitzmanD.W. LindegaardM.L. MøllerD.V. ShahS.J. TreppendahlM.B. VermaS. AbhayaratnaW. AhmedF.Z. ChopraV. EzekowitzJ. FuM. ItoH. LelonekM. MelenovskyV. MerkelyB. NúñezJ. PernaE. SchouM. SenniM. SharmaK. Van der MeerP. von LewinskiD. WolfD. PetrieM.C. Semaglutide in patients with heart failure with preserved ejection fraction and obesity.N. Engl. J. Med.2023389121069108410.1056/NEJMoa230696337622681
     [Google Scholar]
  66. KushnerR.F. CalannaS. DaviesM. DickerD. GarveyW.T. GoldmanB. LingvayI. ThomsenM. WaddenT.A. WhartonS. WildingJ.P.H. RubinoD. Semaglutide 2.4 mg for the treatment of obesity: Key elements of the STEP trials 1 to 5.Obesity (Silver Spring)20202861050106110.1002/oby.2279432441473
     [Google Scholar]
  67. StefanN. CusiK. A global view of the interplay between non-alcoholic fatty liver disease and diabetes.Lan. Diabe. Endocrinol.202210428429610.1016/S2213‑8587(22)00003‑135183303
     [Google Scholar]
  68. LauD.C.W. BatterhamR.L. le RouxC.W. Pharmacological profile of once-weekly injectable semaglutide for chronic weight management.Exp. Rev. Clin. Pharmacol.202215325126810.1080/17512433.2022.207047335466848
     [Google Scholar]
  69. PhillipsA. ClementsJ.N. Clinical review of subcutaneous semaglutide for obesity.J. Clin. Pharm. Ther.202247218419310.1111/jcpt.1357434964141
     [Google Scholar]
  70. TchangB.G. ArasM. KumarR.B. AronneL.J. Pharmacologic treatment of overweight and obesity in adults.Endotext FeingoldK.R. AnawaltB. BlackmanM.R. South Dartmouth (MA)MDText.com, Inc.20151625905267
     [Google Scholar]
  71. WildingJ.P.H. BatterhamR.L. DaviesM. Van GaalL.F. KandlerK. KonakliK. LingvayI. McGowanB.M. OralT.K. RosenstockJ. WaddenT.A. WhartonS. YokoteK. KushnerR.F. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.Diab. Obes. Metab.20222481553156410.1111/dom.1472535441470
     [Google Scholar]
  72. KaragiannisT. AvgerinosI. LiakosA. Del PratoS. MatthewsD.R. TsapasA. BekiariE. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: A systematic review and meta-analysis.Diabetologia20226581251126110.1007/s00125‑022‑05715‑435579691
     [Google Scholar]
  73. FriedrichsenM. BreitschaftA. TadayonS. WizertA. SkovgaardD. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity.Diab. Obes. Metab.202123375476210.1111/dom.1428033269530
     [Google Scholar]
  74. MichałowskaJ. Miller-KasprzakE. BogdańskiP. Incretin hormones in obesity and related cardiometabolic disorders: The clinical perspective.Nutrients202113235110.3390/nu1302035133503878
     [Google Scholar]
  75. QinW. YangJ. DengC. RuanQ. DuanK. Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta‐analysis including the 2‐year step 5 trial.Diab. Obes. Metab.202426391192310.1111/dom.1538638016699
     [Google Scholar]
  76. Tamayo-TrujilloR. Ruiz-PozoV.A. Cadena-UllauriS. Guevara-RamírezP. Paz-CruzE. Zambrano-VillacresR. Simancas-RacinesD. ZambranoA.K. Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity.Front. Nutr.202411139805910.3389/fnut.2024.139805938742021
     [Google Scholar]
  77. FeierC. VonicaR. FaurA. StreinuD. MunteanC. Assessment of thyroid carcinogenic risk and safety profile of GLP1-RA semaglutide (ozempic) therapy for diabetes mellitus and obesity: A systematic literature review.Int. J. Mol. Sci.2024258434610.3390/ijms2508434638673931
     [Google Scholar]
  78. LingvayI. Brown-FrandsenK. ColhounH.M. DeanfieldJ. EmersonS.S. EsbjergS. Hardt-LindbergS. HovinghG.K. KahnS.E. KushnerR.F. LincoffA.M. MarsoS.P. FriesT.M. PlutzkyJ. RyanD.H. Semaglutide for cardiovascular event reduction in people with overweight or obesity: Select study baseline characteristics.Obesity (Silver Spring)202331111112210.1002/oby.2362136502289
     [Google Scholar]
  79. BozkurtB. AguilarD. DeswalA. DunbarS.B. FrancisG.S. HorwichT. JessupM. KosiborodM. PritchettA.M. RamasubbuK. RosendorffC. YancyC. Contributory risk and management of comorbidities of hypertension, obesity, diabetes mellitus, hyperlipidemia, and metabolic syndrome in chronic heart failure: A scientific statement from the american heart association.Circulation201613423e535e57810.1161/CIR.000000000000045027799274
     [Google Scholar]
  80. AmaroA. SugimotoD. WhartonS. Efficacy and safety of semaglutide for weight management: Evidence from the STEP program.Postgrad. Med.2022134sup151710.1080/00325481.2022.214732636691309
     [Google Scholar]
  81. AlabduljabbarK. Al-NajimW. le RouxC.W. The impact once-weekly semaglutide 2.4 mg will have on clinical practice: A focus on the STEP trials.Nutrients20221411221710.3390/nu1411221735684020
     [Google Scholar]
  82. KosiborodM.N. BhattaM. DaviesM. DeanfieldJ.E. GarveyW.T. KhalidU. KushnerR. RubinoD.M. ZeuthenN. VermaS. Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: Step 1 and 4 exploratory analyses.Diab. Obes. Metab.202325246847810.1111/dom.1489036200477
     [Google Scholar]
  83. DjalaliniaS. Saeedi MoghaddamS. SheidaeiA. RezaeiN. Naghibi IravaniS.S. ModirianM. ZokaeiH. YoosefiM. GohariK. KoushaA. AbdiZ. NaderimaghamS. SoroushA.R. LarijaniB. FarzadfarF. Patterns of obesity and overweight in the Iranian population: Findings of STEPs 2016.Front. Endocrinol. (Lausanne)2020114210.3389/fendo.2020.0004232174887
     [Google Scholar]
  84. ChakhtouraM. HaberR. GhezzawiM. RhayemC. TcheroyanR. MantzorosC.S. Pharmacotherapy of obesity: An update on the available medications and drugs under investigation.EClinicalMedicine20235810188210.1016/j.eclinm.2023.10188236992862
     [Google Scholar]
  85. FornesA. HuffJ. PritchardR.I. GodfreyM. Once-weekly semaglutide for weight management: A clinical review.J. Pharm. Technol.202238423924610.1177/8755122522109268135832567
     [Google Scholar]
  86. EneboL.B. BerthelsenK.K. KankamM. LundM.T. RubinoD.M. SatylganovaA. LauD.C.W. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: A randomised, controlled, phase 1b trial.Lancet2021397102861736174810.1016/S0140‑6736(21)00845‑X33894838
     [Google Scholar]
  87. ChiappiniS. Vickers-SmithR. HarrisD. Papanti PelletierG.D. CorkeryJ.M. GuirguisA. MartinottiG. SensiS.L. SchifanoF. Is there a risk for semaglutide misuse? Focus on the Food and Drug Administration’s FDA Adverse Events Reporting System (FAERS) pharmacovigilance dataset.Pharmaceuticals (Basel)202316799410.3390/ph1607099437513906
     [Google Scholar]
  88. SchultzM.J. HarmsenR.E. SpronkP.E. Clinical review: Strict or loose glycemic control in critically ill patients - implementing best available evidence from randomized controlled trials.Crit. Care201014322310.1186/cc896620550725
     [Google Scholar]
  89. LingvayI. DesouzaC.V. LalicK.S. RoseL. HansenT. ZachoJ. PieberT.R. A 26-week randomized controlled trial of semaglutide once daily versus liraglutide and placebo in patients with type 2 diabetes suboptimally controlled on diet and exercise with or without metformin.Diab. Care20184191926193710.2337/dc17‑238130026333
     [Google Scholar]
  90. Di LoretoC. MinarelliV. NasiniG. NorgioliniR. Del SindacoP. Effectiveness in real world of once weekly semaglutide in people with type 2 diabetes: Glucagon-like peptide receptor agonist naïve or switchers from other glucagon-like peptide receptor agonists: Results from a retrospective observational study in Umbria.Diab. Ther.202213355156710.1007/s13300‑022‑01218‑y35230650
     [Google Scholar]
  91. DengY. ParkA. ZhuL. XieW. PanC.Q. Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: A systematic review.Ther. Adv. Chronic Dis.2022132040622322110806410.1177/2040622322110806435813188
     [Google Scholar]
  92. XieZ. YangS. DengW. LiJ. ChenJ. Efficacy and safety of liraglutide and semaglutide on weight loss in people with obesity or overweight: A systematic review.Clin. Epidemiol.2022141463147610.2147/CLEP.S39181936510488
     [Google Scholar]
  93. NuhohoS. GuptaJ. HansenB.B. Fletcher-LouisM. Dang-TanT. PaineA. Orally administered semaglutide versus GLP-1 RAs in patients with type 2 diabetes previously receiving 1–2 oral antidiabetics: Systematic review and network meta-analysis.Diab. Ther.20191062183219910.1007/s13300‑019‑00706‑y31599391
     [Google Scholar]
  94. NevolaR. EpifaniR. ImbrianiS. TortorellaG. ApreaC. GalieroR. RinaldiL. MarfellaR. SassoF.C. GLP-1 receptor agonists in non-alcoholic fatty liver disease: Current evidence and future perspectives.Int. J. Mol. Sci.2023242170310.3390/ijms2402170336675217
     [Google Scholar]
  95. WrightE.E.Jr ArodaV.R. Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy.Postgra. Med.2020132sup2263610.1080/00325481.2020.179812732815423
     [Google Scholar]
  96. HuangC. The role of semaglutide in weight management: An analysis of clinical studies for overweight and obese adults.J. Educ. Humani. Soc. Sci.202427551558
     [Google Scholar]
  97. AlromaihA. AlshamraniA. AlharbiB. AlharbiI. AlharbiT. BokhariS. ElbadawiH. AlmehthelM. AlsaeedA. AlyahiaK. AlhowyanF. EvansM. MehtaR. IssakE. AlsifriS. Saudi consensus for oral semaglutide, the recent innovation in GLP-1 RAS era; Consensus report.J. Diabe. Melli.202313222223810.4236/jdm.2023.132017
     [Google Scholar]
  98. LombardL. ‘Diabesity’–interlinking treatments to improve outcomes in diabetes and obesity.Denovo. Med.20201112
     [Google Scholar]
  99. LandgrafR. AberleJ. BirkenfeldA.L. Therapy of type 2 diabetes.Exp. Clin. Endocrinol. Diabe.2022130S01S80S11210.1055/a‑1624‑344935839797
     [Google Scholar]
  100. FernandoK. BainS.C. HolmesP. JonesP.N. PatelD.C. Glucagon-like peptide 1 receptor agonist usage in type 2 diabetes in primary care for the UK and beyond: A narrative review.Diab. Ther.20211292267228810.1007/s13300‑021‑01116‑934309808
     [Google Scholar]
  101. TakahashiY. NomotoH. YokoyamaH. TakanoY. NagaiS. TsuzukiA. ChoK.Y. MiyaA. KamedaH. TakeuchiJ. TanedaS. KuriharaY. AtsumiT. NakamuraA. MiyoshiH. Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open‐label, parallel‐group comparison study ( switch‐sema 1 study).Diab. Obes. Metab.20232561503151110.1111/dom.1499836722623
     [Google Scholar]
  102. MorieriM.L. AvogaroA. FadiniG.P. Long-acting injectable GLP-1 receptor agonists for the treatment of adults with type 2 diabetes: Perspectives from clinical practice.Diab. Metab. Syndr. Obes.2020134221423410.2147/DMSO.S21605433204129
     [Google Scholar]
  103. TilincaM. TiucaR. NiculasC. VargaA. TileaI. Future perspectives in diabesity treatment: Semaglutide, a glucagon‑like peptide 1 receptor agonist (Review).Exp. Ther. Med.2021224116710.3892/etm.2021.1060134504612
     [Google Scholar]
  104. ShuY. HeX. WuP. LiuY. DingY. ZhangQ. Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system.Front. Publ. Heal.20221099617910.3389/fpubh.2022.99617936339230
     [Google Scholar]
  105. WhartonS. CalannaS. DaviesM. DickerD. GoldmanB. LingvayI. MosenzonO. RubinoD.M. ThomsenM. WaddenT.A. PedersenS.D. Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss.Diab. Obes. Metab.20222419410510.1111/dom.1455134514682
     [Google Scholar]
  106. AhrénB. AtkinS.L. CharpentierG. WarrenM.L. WildingJ.P.H. BirchS. HolstA.G. LeiterL.A. Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline bmi or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials.Diab. Obes. Metab.20182092210221910.1111/dom.1335329766634
     [Google Scholar]
  107. SharmaA. ParachuriN. KumarN. SabooB. TripathiH.N. KuppermannB.D. BandelloF. Semaglutide and the risk of diabetic retinopathy—current perspective.Eye (Lond.)2022361101110.1038/s41433‑021‑01741‑534373613
     [Google Scholar]
  108. VilsbøllT. BainS.C. LeiterL.A. LingvayI. MatthewsD. SimóR. HelmarkI.C. WijayasingheN. LarsenM. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy.Diab. Obes. Metab.201820488989710.1111/dom.1317229178519
     [Google Scholar]
  109. Cigrovski BerkovicM. StrolloF. Semaglutide-eye-catching results.World J. Diab.202314442443410.4239/wjd.v14.i4.42437122431
     [Google Scholar]
  110. RichardsR. WrenG.M. CampionP. WhitmanM. A remotely delivered, semaglutide-supported specialist weight management program: Preliminary findings from a retrospective service evaluation.JMIR Form. Res.202371e5361910.2196/5361938153780
     [Google Scholar]
/content/journals/cst/10.2174/0115743624346660250317013032
Loading
Utilizing Semaglutide for Addressing Type-2 Diabetes and Obesity
Current Signal Transduction Therapy 20, E15743624346660 (2025); https://doi.org/10.2174/0115743624346660250317013032
/content/journals/cst/10.2174/0115743624346660250317013032
/content/journals/cst/10.2174/0115743624346660250317013032
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): GLP-1; incretin; Obesity; SNAC; STEP; type-2 diabetes mellitus
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test